KR970705405A - Human Chemokine Polypeptides < RTI ID = 0.0 > - Google Patents

Abstract

Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Description

Human Chemokine Polypeptides < RTI ID = 0.0 >

Since this is a trivial issue, I did not include the contents of the text.

Claims (30)

(a) a polynucleotide encoding a Ck? -4 polypeptide having the deduced amino acid sequence of FIG. 1 or a fragment, homologue or derivative of said polypeptide; (b) a polynucleotide encoding a Ck [beta] -4 polypeptide encoded by the cDNA contained in ATCC Accession No. 75848 or a fragment, homolog or derivative of said polypeptide; (c) a polynucleotide encoding a Ck? -10 polypeptide having the deduced amino acid sequence of FIG. 2 or a fragment, homologue or derivative of said polypeptide; And (d) a polynucleotide selected from the group consisting of a Ck [beta] -10 polypeptide encoded by the cDNA contained in ATCC Accession No. 75849 or a polynucleotide encoding a fragment, homologue or derivative of said polypeptide. The polynucleotide according to claim 1, wherein the polynucleotide is DNA. The polynucleotide according to claim 1, wherein the polynucleotide is RNA. 2. The polynucleotide of claim 1, wherein the polynucleotide is genomic DNA. 3. The polynucleotide of claim 2, wherein the polynucleotide comprises a polynucleotide encoding Ck [beta] -4 having the deduced amino acid sequence of Figure 2; 3. The polynucleotide of claim 2, wherein the polynucleotide encodes Ck [beta] -10 having the deduced amino acid sequence of Figure 3; 3. The polynucleotide of claim 2, wherein the polynucleotide comprises a polynucleotide encoding a Ck [beta] -4 polypeptide encoded by the cDNA of Deposit No. 75848; 3. The polynucleotide of claim 2, wherein the polynucleotide comprises a polynucleotide encoding a Ck [beta] -4 polypeptide encoded by the cDNA of Deposit No. 75849; 2. The polynucleotide of claim 1, having the coding sequence of Ck beta-4 as shown in FIG. 3. The polynucleotide according to claim 2, which has a coding sequence of Ck beta-10 as shown in Figure 2; 3. The polynucleotide of claim 2, having the coding sequence of Ck beta-4 deposited as ATCC Deposit No. 75848. 3. The polynucleotide of claim 2, having the coding sequence of Ck beta-10 deposited as ATCC Deposit No. 75849. A vector containing the DNA of claim 2. A host cell genetically engineered by the vector of claim 13. 15. A method for producing a polypeptide, comprising the step of expressing a polypeptide encoded by said DNA from the host cell of claim 14. 13. A method of producing a cell capable of expressing a polypeptide, comprising the step of genetically manipulating the cell using the vector of claim 13. A separate DNA encoding a polypeptide of claim 2 and a highly drivable polypeptide having Ck beta-4 activity. The isolated DNA encoding the polypeptide of claim 2 and a highly drivable polypeptide having Ck beta-10 activity. (I) a Ck? -4 polypeptide having the deduced amino acid sequence of FIG. 1 or a fragment, homologue or derivative thereof, (ii) a Ck? -4 polypeptide encoded by a cDNA containing ATCC Accession No. 75848 or (Iii) a polynucleotide encoding a Ck [beta] -10 polypeptide having the deduced amino acid sequence of FIG. 2 or a fragment, homologue or derivative of said polypeptide; And (d) a Ck β-10 polypeptide encoded by the cDNA contained in ATCC Accession No. 75849 or a fragment, homolog or derivative thereof, and (iv) a Ck β-10 polypeptide encoded by the cDNA of ATCC Deposit No. 75849, 10 polypeptides or polypeptides selected from the group consisting of fragments, analogs or derivatives of said polypeptides. 20. The polynucleotide of claim 19, wherein the polynucleotide is selected from the group consisting of a Ck [beta] -4 polypeptide having the deduced amino acid sequence of Figure 1, 20. The polynucleotide of claim 19, wherein the polynucleotide is selected from the group consisting of a Ck [beta] -10 polypeptide having the deduced amino acid sequence of Figure 2, 26. An antibody against the polypeptide of claim 19. 19. An antagonist of the polypeptide of claim 19. 19. A method of treating a patient in need of Ck [beta] -4, comprising administering a therapeutically effective amount of the polypeptide of claim 19 to a patient in need of Ck [beta] -4. 24. A method of treating a patient in need of inhibition of Ck beta-4, comprising administering a therapeutically effective amount of the antagonist of claim 23 to a patient in need of inhibition of Ck beta-4. 20. A method of treating a patient in need of Ck beta-10, comprising administering to a patient in need of such treatment a therapeutically effective amount of the polypeptide of claim 19. 10. A method of treating a patient in need of inhibition of Ck beta-10, comprising administering to a patient in need thereof a therapeutically effective amount of an antagonist of claim 23. 20. A pharmaceutical composition comprising one of the polypeptides of claim 19 and a pharmaceutically acceptable carrier. 25. The method of claim 24, wherein a therapeutically effective amount of the polypeptide is administered to a patient by providing the patient with DNA encoding the polypeptide to cause the polypeptide to be expressed in vivo. 27. The method of claim 26, wherein a therapeutically effective amount of the polypeptide is administered to a patient by providing the patient with DNA encoding the polypeptide to cause the polypeptide to be expressed in vivo. ※ Note: It is disclosed by the contents of the first application.